|
|
Article: Bristol-Myers Squibb and The Gillette Company Announce FDA Approval Of VANIQA(TM)(eflornithine hydrochloride) Cream, 13.9% as Treatment For Women With Unwanted Facial Hair.
- Article from:
- PR Newswire
- Article date:
- July 31, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Approval of First Prescription Product of Its Kind is Important News
For the More Than 41 Million Women with This Condition
PRINCETON, N.J., July 31 /PRNewswire/ --
Bristol-Myers Squibb Company (NYSE: BMY) and The Gillette Company (NYSE: G) announced today that the U.S. Food and Drug Administration has approved VANIQA(TM) (eflornithine hydrochloride) Cream, 13.9% as the first topical prescription treatment for women with unwanted facial hair. VANIQA works by inhibiting the growth of facial hair, and was shown in controlled clinical trials to provide clinically meaningful and statistically significant improvement in the reduction of facial hair ...